4,218 results match your criteria Thyroid Ophthalmopathy


Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves' Ophthalmopathy: Good Results After Long-Term Follow-Up.

Int J Endocrinol Metab 2019 Jan 27;17(1):e84427. Epub 2019 Jan 27.

Department of Radiation Oncology, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy.

Background: Orbital radiotherapy (RT) is an effective and consolidate treatment for steroid-refractory Graves' ophthalmopathy (GO); however, long term effects are not well known.

Objectives: The aim of this study was to evaluate the long term efficacy and toxicity of orbital RT plus concomitant systemic steroids in a population of patients with moderate-to-severe GO or with eyesight threatening symptoms refractory to steroids.

Methods: Forty patients with moderate-to-severe GO or with eyesight threatening symptoms not responsive/resistant to steroids were treated with orbital RT at the dose of 20 Gy in 10 fractions plus concomitant steroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5812/ijem.84427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408739PMC
January 2019

Early Low Dose Rituximab for Active Thyroid Eye Disease: An Effective and Well Tolerated Treatment.

Clin Endocrinol (Oxf) 2019 Mar 13. Epub 2019 Mar 13.

Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK.

Background: Thyroid eye disease (TED) is an autoimmune inflammatory disease that can be disfiguring and potentially sight threatening. Suppression of inflammation in active disease can reduce the risk of visual loss and limit long-term sequelae. Current management involves inflammation suppression using glucocorticoids. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cen.13970
Publisher Site
http://dx.doi.org/10.1111/cen.13970DOI Listing
March 2019
4 Reads

Does the dose of iodine-131 influence the incidence of Graves' ophthalmopathy?

Nucl Med Commun 2019 Mar 6. Epub 2019 Mar 6.

Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Temple University Health System.

Background: Radioactive iodine-131 (RAI) is an established treatment for patients with Graves' hyperthyroidism. RAI is reported to be associated with a 20-30% incidence of development or exacerbation of Graves' ophthalmopathy (GO). This study compares the progression of GO in patients who had evidence or no evidence of GO before RAI therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000001008DOI Listing
March 2019
2 Reads

Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy.

Endocrinol Diabetes Metab J 2019 Feb 8;3(1). Epub 2019 Jan 8.

Division of Endocrinology, Harbor-UCLA Medical Center and the David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Purpose: To report a case of orbital fat expansion leading to globe prolapse in a Graves' disease patient undergoing high-dose glucocorticoid therapy. To evaluate the growth factor receptor specificities of plasma autoantibodies in Graves' disease patients who exhibited contrasting subtypes of thyroid-associated ophthalmopathy, i.e. Read More

View Article

Download full-text PDF

Source
February 2019

Rare Co-occurrence of Ocular Myasthenia Gravis and Thyroid-Associated Orbitopathy (Ophthalmopathy) in an Individual With Hypothyroidism.

Front Endocrinol (Lausanne) 2018 12;9:801. Epub 2019 Feb 12.

Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.

Ocular myasthenia gravis (Ocular MG, OMG) shares many clinical features with thyroid-associated orbitopathy or thyroid-associated ophthalmopathy (TAO). In the rare instance of their coexistence, clinicians may fail to diagnose ocular MG when TAO is also present. Here we report the case of a patient with both TAO and ocular MG, whose "hyperthyroidism"-most likely the hashitoxicosis variant of Hashimoto's thyroiditis-rapidly transformed to hypothyroidism after radioactive iodine therapy. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fendo.2018.00801
Publisher Site
http://dx.doi.org/10.3389/fendo.2018.00801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379256PMC
February 2019
2 Reads

[Antifibrotic effect of pirfenidone on orbital fibroblasts in patients with thyroid-associated ophthalmopathy and its mechanisms].

Zhonghua Nei Ke Za Zhi 2019 Mar;58(3):185-190

Department of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, China.

To investigate the effects of pirfenidone on orbital fibroblasts (OFs) from patients with thyroid-associated ophthalmopathy (TAO) and its underlying mechanisms. OFs from patients with TAO were isolated and cultured in DMEM. Cells were divided into four groups and treated with 0, 250, 500 and 1 000 μg/ml pirfenidone for 24, 48 or 72 hours, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2019.03.007DOI Listing
March 2019
2 Reads

A novel method for quantifying the biomechanical parameters of orbital soft tissue using a corneal dynamic scheimpflug analyser: a retrospective study.

BMC Ophthalmol 2019 Feb 18;19(1):53. Epub 2019 Feb 18.

Department of Ophthalmology, Seoul St. Mary's Hospital, Catholic University of Korea, Banpodaero 222, Seocho-gu, Seoul, South Korea.

Background: To demonstrate that the Corvis ST could be used to quantify the biomechanical parameters of the orbital soft tissues by measuring and comparing whole eye movement (WEM) using the Corvis in normal eyes and in eyes of patients with Graves ophthalmopathy.

Methods: Forty four eyes of 44 ophthalmologically normal subjects and 28 eyes of 28 patients with Graves ophthalmopathy were included in the study. After Corvis test, the examiners recorded WEM by air puff. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12886-019-1064-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380054PMC
February 2019
1 Read

Gene Variations Confer Susceptibility to Autoimmune Thyroid Diseases and Graves' Ophthalmopathy.

Int J Endocrinol 2019 15;2019:7429187. Epub 2019 Jan 15.

Department of Endocrinology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong District, Shanghai 201318, China.

The objective of this study was to investigate whether polymorphisms are associated with autoimmune thyroid diseases (AITDs). We selected three single nucleotide polymorphisms (SNPs) of , namely, rs1061501, rs1131665, and rs1061502 for genotyping using PCR-based ligase detection reaction (LDR) method in a total of 1659 participants (592 with Graves' disease, 297 with Hashimoto's thyroiditis, and 770 healthy controls). Gene-disease and genotype-clinical phenotype associations were evaluated for the three SNPs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7429187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350596PMC
January 2019
3 Reads

Recommendations for ultrasound examination in ophthalmology. Part II: Orbital ultrasound.

J Ultrason 2018 ;18(75):349-354

Imperial College NHS Trust, Western Eye Hospital , London , UK.

Pathological processes within the orbits are a heterogeneous group of diseases of various etiologies, clinical pictures and therapy models. Due to poor access to the orbits in a clinical examination, imaging plays a significant role in both diagnosis and treatment monitoring in patients with an orbital pathology. One of such imaging modalities is ultrasonography. Read More

View Article

Download full-text PDF

Source
http://jultrason.pl/index.php/issues/volume-18-no-75/recomme
Publisher Site
http://dx.doi.org/10.15557/JoU.2018.0051DOI Listing
January 2018
5 Reads

A Rare Case of Bilateral Proptosis.

Eur J Case Rep Intern Med 2018 28;5(11):000966. Epub 2018 Nov 28.

Medicine IV Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal.

A 65-year-old man presented with a 2-year history of severe bilateral proptosis, palpable lymphadenopathy and moderate hepatosplenomegaly. A blood test was positive for hepatitis C infection. CT showed palpebral infiltrative lesions with regional progression through the temporal and masticatory spaces to the pharynx and hypopharynx causing almost complete airway obstruction. Read More

View Article

Download full-text PDF

Source
https://www.ejcrim.com/index.php/EJCRIM/article/view/966
Publisher Site
http://dx.doi.org/10.12890/2018_000966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346810PMC
November 2018
5 Reads

Altered Corneal Nerves in Chinese Thyroid-Associated Ophthalmopathy Patients Observed by In Vivo Confocal Microscopy.

Med Sci Monit 2019 Feb 6;25:1024-1031. Epub 2019 Feb 6.

Department of Ophthalmology, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland).

BACKGROUND Thyroid-associated ophthalmopathy (TAO) is a common endocrine autoimmune disease. The present study explored corneal nerve changes in TAO patients. MATERIAL AND METHODS Thirty-eight Chinese TAO patients and 20 healthy individuals were included in the study. Read More

View Article

Download full-text PDF

Source
https://www.medscimonit.com/abstract/index/idArt/912310
Publisher Site
http://dx.doi.org/10.12659/MSM.912310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373222PMC
February 2019
5 Reads

[Update Graves' disease 2019].

Dtsch Med Wochenschr 2019 Feb 31;144(3):152-155. Epub 2019 Jan 31.

Funktionsbereich Spezielle Endokrinologie, Universitätsklinikum Düsseldorf.

Diagnosis:  Also accordingly to the recent European Thyroid Association Guidelines 2018, TSH receptor antibody (TRAb) measurement is highly sensitive and specific for the detection of Graves' disease (GD) and to distinguish from autoimmune thyroiditis (AIT). Bioassays are used for distinguishing stimulating from blocking antibodies and are used for scientific questions.

Therapy:  According to the current guidelines - and with exception for pregnant women - the use of thiamazol/carbimazole is generally favored from propylthiouracil (PTU). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0660-6046DOI Listing
February 2019
16 Reads

Association between polymorphic markers in candidate genes and the risk of manifestationof endocrine ophthalmopathy in patients with Graves' disease.

Ter Arkh 2018 Nov;90(10):35-39

N.M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.

Aim: To analyze the association between the polymorphic markers in CTLA4, TNF, IL10 and IL16 genes and the risk of manifestation of endocrine ophthalmopathy (EO) in patients with Graves' disease (GD).

Materials And Methods: Case-control study included 248 patients with GD. Using polymerase chain reaction we studied the distribution of alleles and genotypes of polymorphic markers such as A60G (rs3087243) in CTLA4 gene, G(-308)A (rs1800629) in TNF gene, G(-1082)A (rs1800896) in IL10 gene, T3249C (rs4778641) in IL16 gene among 141 patients with Graves' disease and EO and 107 patients with GD without EO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh2018901035-39DOI Listing
November 2018
1 Read

IgG4-related disease in endocrine practice.

Arch Med Sci 2019 Jan 20;15(1):55-64. Epub 2017 Oct 20.

Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland.

IgG4-related disease is a set of symptoms resulting from a chronic, usually multiple organ inflammatory condition which affects various organs. It consists of lymphoplasmacytic infiltrations with attendant fibrosis and deep vein thrombosis. Frequently observed tissue lesions are accompanied by elevated IgG4 levels in serum. Read More

View Article

Download full-text PDF

Source
https://www.termedia.pl/doi/10.5114/aoms.2017.70889
Publisher Site
http://dx.doi.org/10.5114/aoms.2017.70889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348348PMC
January 2019
15 Reads

Analysis in Choroidal Thickness in Patients with Graves' Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography.

J Ophthalmol 2018 23;2018:3529395. Epub 2018 Dec 23.

Department of Ophthalmology, First Hospital, Peking University, Beijing, China.

Objectives: The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves' ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT).

Methods: The right eyes of 36 patients (27 females and 9 males) with Graves' ophthalmopathy (GO) and those of 36 age-, gender-, and diopter-level-matched healthy participants were evaluated. The patients' data were obtained within 3 months after the onset of Graves' disease (GD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3529395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323464PMC
December 2018
6 Reads

The management of large-angle esotropia in Graves ophthalmopathy with combined medial rectus recession and lateral rectus resection.

J AAPOS 2019 Jan 18. Epub 2019 Jan 18.

Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon.

Purpose: To describe surgical management and outcomes for large-angle esotropia of ≥50 secondary to Graves ophthalmopathy using combined initial nonadjustable medial rectus recessions and lateral rectus resections.

Methods: The medical records of consecutive patients undergoing strabismus surgery for large-angle esotropia secondary to Graves ophthalmopathy from 1995 to 2012 by a single surgeon at each of two institutions was performed. Patient characteristics, surgical technique, and pre- and postoperative measurements of ocular alignment were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaapos.2018.08.013DOI Listing
January 2019
2 Reads

Assessment of tear-evaporation rate in thyroid-gland patients.

Clin Ophthalmol 2019 7;13:131-135. Epub 2019 Jan 7.

Department of Optometry, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia,

Objective: To assess the tear-evaporation rate in thyroid-gland patients using a VapoMeter.

Methods: Twenty thyroid gland patients aged 18-43 years (mean 34.3±6. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/assessment-of-tear-evaporation-rat
Publisher Site
http://dx.doi.org/10.2147/OPTH.S188614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327900PMC
January 2019
7 Reads

Effect of orbital decompression on dysthyroid optic neuropathy: A retrospective case series.

Medicine (Baltimore) 2019 Jan;98(3):e14162

Department of Ophthalmology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi.

In this study, we try to explore the effect of orbital decompression treatment on severe dysthyroid optic neuropathy.We retrospectively collected demographic and clinical characteristics of thyroid eye disease patients who performed orbital decompression. Then we analyzed the change of best-corrected visual acuity and exophthalmometry after surgery and the correlations among clinical parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370065PMC
January 2019
1 Read

The impact of orbital bony or fat decompression on the outcome of strabismus surgery in patients with Graves' ophthalmopathy.

J Formos Med Assoc 2019 Jan 7;118(1 Pt 3):387-394. Epub 2018 Jul 7.

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan; School of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:

Background/purpose: To compare the outcomes of strabismus surgery in patients with Graves' ophthalmopathy (GO) who had undergone bone removal orbital decompression (BROD) or fat removal orbital decompression (FROD) with those who had not undergone any orbital decompression.

Methods: The records of patients with GO who underwent strabismus surgery over a period of 66 months were retrospectively reviewed.

Results: Eighty-nine patients with a mean age of 55. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfma.2018.06.009DOI Listing
January 2019
2 Reads

The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series.

Autoimmun Rev 2019 Mar 11;18(3):287-292. Epub 2019 Jan 11.

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, Pisa 56126, Italy. Electronic address:

Graves' disease (GD) and autoimmune thyroiditis (AT) are the two main clinical presentations of AITD, and their clinical hallmarks are thyrotoxicosis and hypothyroidism, respectively. GD, and AT, can be associated with other organ specific, or systemic autoimmune diseases in the same patient. However discordant results have been reported in the literature about the possible associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.001DOI Listing
March 2019
15 Reads

Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?

Int J Environ Res Public Health 2019 Jan 8;16(1). Epub 2019 Jan 8.

Paediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, 06129 Perugia, Italy.

Background: Ophthalmopathy is a rare extra-thyroid manifestation of Graves' disease, in paediatrics. Intravenous corticosteroids are the main treatment of moderate-to-severe Graves' orbitopathy. In this paper, we describe a moderate-to-severe active Graves' ophthalmopathy in a child and the response to oral therapy with prednisone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijerph16010155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339077PMC
January 2019
1 Read

Introduction to the Theme "New Therapeutic Targets".

Annu Rev Pharmacol Toxicol 2019 Jan;59:15-20

Biozentrum, University of Basel, CH-4056 Basel, Switzerland.

"New Therapeutic Targets" is the theme of articles in the Annual Review of Pharmacology and Toxicology, Volume 59. Reviews in this volume discuss targets for a variety of conditions in need of new therapies, including type 2 diabetes, heart failure with preserved ejection fraction, obesity, thyroid-associated ophthalmopathy, tinnitus, multiple sclerosis, Parkinson's disease and other neurodegenerative diseases, pain, depression, post-traumatic stress disorder, muscle wasting diseases, cancer, and anemia associated with chronic renal disease. Numerous articles in this volume focus on the identification, validation, and utility of novel therapeutic targets, in particular, ones that involve new or unexpected molecular entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-pharmtox-101018-112717DOI Listing
January 2019
3 Reads

Severe unilateral orbitopathy in a patient with Hashimoto's thyroiditis - a case report.

BMC Ophthalmol 2019 Jan 8;19(1). Epub 2019 Jan 8.

Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.

Background: Thyroid-associated orbitopathy (TAO) constitutes an immune-mediated inflammation of the orbital tissues of unclear etiopathogenesis. TAO is most prevalent in hyperthyroid patients with Graves' disease (GD); however, severe cases of orbitopathy associated with Hashimoto's thyroiditis (HT) have rarely been described.

Case Presentation: Herewith we report an unusual case of a middle-aged clinically and biochemically euthyroid woman with a stable HT, who developed a severe unilateral left-sided TAO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12886-018-1018-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325776PMC
January 2019
10 Reads

The relationship between thyroid eye disease and radioiodine treatment.

Nucl Med Commun 2019 Mar;40(3):194-198

Department of Nuclear Medicine, National Cancer Center, Calmette University Hospital, Phnom Penh, Cambodia.

Thyroid eye disease is the most frequent extrathyroidal manifestation of Graves' disease and it can have a major negative impact on the quality of life of affected patients. Therefore, it is crucial to have a correct and early diagnosis. Thyroid eye disease management should be multidisciplinary. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00006231-900000000-9845
Publisher Site
http://dx.doi.org/10.1097/MNM.0000000000000965DOI Listing
March 2019
7 Reads

Effect of antithyroid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves' disease influencing the therapeutic efficacy.

Clin Exp Med 2019 Jan 4. Epub 2019 Jan 4.

Immunoendocrinology, EndoMed, Bem tér 18/C., Debrecen, 4026, Hungary.

Graves' disease is an organ-specific autoimmune disease with hyperthyroidism, diffuse goiter and autoantibodies against TSH receptor, thyroid peroxidase (TPO) and/or thyroglobulin (Tg). Graves' hyperthyroidism is characterized by T dominance due to the conversion of T into T through type 1 and 2 deiodinase enzymes (DIO1, DIO2). Methimazole (MMI) and propylthiouracil (PTU) therapies inhibit thyroid hormone synthesis blocking the activity of deiodinase and TPO enzymes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10238-018-00542-7DOI Listing
January 2019
4 Reads

Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases.

Crit Rev Clin Lab Sci 2019 Jan 3;56(1):18-32. Epub 2019 Jan 3.

a Tianjin Medical University Eye Hospital , Tianjin Medical University Eye Institute, School of Optometry and Ophthalmology, Tianjin Medical University , Tianjin , China.

Programmed death receptor-1 (PD-1) and its ligand, PD-L1, as negative co-stimulatory molecules, are indispensable for regulating both physiological and pathological immune responses. The PD-1/PD-L1-mediated signaling pathway has been studied extensively in cancer research and has become a hotspot for biopharmaceuticals and immunotherapy. Furthermore, monoclonal antibodies to PD-1 have just been approved by the US Food and Drug Administration to treat certain types of malignancies. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10408363.2018.1
Publisher Site
http://dx.doi.org/10.1080/10408363.2018.1522292DOI Listing
January 2019
20 Reads

Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis.

Biomed Res Int 2018 22;2018:4845894. Epub 2018 Nov 22.

Department of Endocrinology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

Background: Graves' ophthalmopathy (GO) is a complicated autoimmune disease. Various therapies have been used to manage GO; however the optimum therapy is not clear. Glucocorticoids (GCs) therapy is the mainstay of treatment especially for active moderate to severe patients, which needs evidence-based support. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/4845894DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282115PMC
November 2018
3 Reads

Study of Deiodinase Type 2 Polymorphisms in Graves' Disease and Ophthalmopathy in a Swedish Population.

Eur Thyroid J 2018 Nov 20;7(6):289-293. Epub 2018 Jul 20.

Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden.

Background: Deiodinase type 2 (DIO2) is an enzyme that catalyzes the production of the active form of thyroid -hormone triiodothyronine (T3) from thyroxine (T4) and is important for maintaining intracellular T3 levels. Single nucleotide polymorphisms (SNPs) in DIO2 were associated with several diseases. The association of SNPs in DIO2 with Graves' disease (GD) was suggested in 2 Russian studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276746PMC
November 2018
1 Read

Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy.

Clin Ophthalmol 2018 27;12:2415-2421. Epub 2018 Nov 27.

Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan,

Purpose: This study was performed to observe changes prospectively in exophthalmos and orbital fat in patients with inactive thyroid-associated ophthalmopathy (TAO) treated with bimatoprost.

Methods: In this 12-month single-treatment pilot observational study, 13 patients with inactive-phase TAO were administered bimatoprost to treat exophthalmos due to TAO. Exophthalmos values and orbital tissue volumes were measured on MRI by technicians in a masked fashion. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/treatment-with-bimatoprost-for-exo
Publisher Site
http://dx.doi.org/10.2147/OPTH.S187164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267500PMC
November 2018
3 Reads

Response to Letter to the Editor: "Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy".

J Clin Endocrinol Metab 2019 Apr;104(4):1077-1078

Departments of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-02282DOI Listing
April 2019
4 Reads

The expression of interleukin-15 and interleukin-17 in tears and orbital tissues of Graves ophthalmopathy patients.

Authors:
Qun Chen

J Cell Biochem 2019 Apr 19;120(4):6299-6303. Epub 2018 Dec 19.

Department of Ophthalmology, Shanghai Gongli Hospital, Shanghai, China.

Objective: The objective of this study was to study the levels of interleukin (IL)-15 and IL-17 in tears and orbital tissues of the patients with the Graves ophthalmopathy (GO) (active and inactive stages) and in controls.

Methods: Twenty-four active GO patients (CAS ≥ 3/7) were collected in our research. All patients were treated with corticosteroids during the therapy process (4-15 months) and developed into the inactive phase (CAS ≤ 2/7). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.27916
Publisher Site
http://dx.doi.org/10.1002/jcb.27916DOI Listing
April 2019
3 Reads

Novel role of SF1 in alleviating thyroid-associated ophthalmopathy through the AMPK/mTOR signaling pathway.

Gene 2019 Apr 15;691:132-140. Epub 2018 Dec 15.

Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Beijing, China. Electronic address:

Background/aim: Thyroid-associated ophthalmopathy (TAO) is a chronic autoimmune disorder characterized by an increased volume of adipose/connective tissue. This study aims to explore whether steroidogenic factor 1 (SF1) is implicated in development of TAO through the adenosine monophosphate-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling pathway.

Methods: Initially, we extracted orbital preadipocytes from 10 TAO patients for culture and identification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2018.11.097DOI Listing
April 2019
3 Reads

Letter to the Editor: "Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy".

J Clin Endocrinol Metab 2019 Apr;104(4):1075-1076

Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/advance-article/doi/10.1210/jc
Publisher Site
http://dx.doi.org/10.1210/jc.2018-02103DOI Listing
April 2019
2 Reads

Thiol-disulfide homeostasis as an oxidative stress marker in patients with Graves' ophthalmopathy.

Orbit 2018 Dec 18:1-6. Epub 2018 Dec 18.

c Medical Faculty, Medical Biochemistry Department , Yıldırım Beyazıt University , Ankara , Turkey.

Purpose: To evaluate thiol-disulfide homeostasis (TDH) and its relationship with clinical findings in patients with Graves' ophthalmopathy (GO).

Methods: This study included 52 patients with GO and 34 healthy controls. Tests of TDH were conducted using the novel automated spectrophotometric method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01676830.2018.1553191DOI Listing
December 2018
2 Reads

The epidemiological characteristics of patients with thyroid eye disease in a referral center in northern Iran.

J Curr Ophthalmol 2018 Dec 19;30(4):353-358. Epub 2018 Jul 19.

Eye Research Center, Guilan University of Medical Sciences, Rasht, Iran.

Purpose: This study was conducted to determine the demographics, clinical features, severity, and activity of thyroid eye disease (TED) in patients of a referral center in the north of Iran.

Methods: Patients with TED who were referred to Amir-Almomenin Hospital, Rasht, Iran from March 2012 to March 2014 were enrolled in this cross-sectional study. The measurements of proptosis, lid width, lagophthalmos, extraocular muscle function, and visual acuity were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.joco.2018.07.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276727PMC
December 2018
1 Read

Rapid Development of Graves' Ophthalmopathy After Treatment With Ipilimumab and Recurrence With Pembrolizumab in a Patient With Previously Treated Graves' Disease.

J Oncol Pract 2018 Dec;14(12):747-749

Inova Fairfax Hospital and Inova Schar Cancer Institute, Falls Church, VA; and Seoul National University Hospital, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00442DOI Listing
December 2018
6 Reads

The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy.

Eye (Lond) 2019 Feb 7;33(2):176-182. Epub 2018 Dec 7.

Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 200011, Shanghai, China.

Thyroid-associated ophthalmoapthy (TAO) is the most common orbital disease. As an autoimmune disorder, it is caused by self-reactive lymphocytes that escape immune tolerance, but the mechanism is not fully understood. The basic process of TAO is the infiltration of immune cells in orbital tissues, the activation of orbital fibroblasts (OFs), and the proliferation and differentiation of OFs and lymphocytes. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41433-018-0279-9
Publisher Site
http://dx.doi.org/10.1038/s41433-018-0279-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367411PMC
February 2019
14 Reads

Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.

Endocrine 2018 Dec 1. Epub 2018 Dec 1.

Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.

Purpose: To evaluate the influence of intravenous methylprednisolone (IVMP) pulse administration on bone mineral density (BMD) of the lumbar spine and the femoral neck in patients with moderate-to-severe Graves' orbitopathy (GO).

Methods: Thirty-five patients with GO in euthyreosis were treated with 12 IVMP pulses (6 × 0.5 g, 6 × 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-018-1823-xDOI Listing
December 2018
6 Reads

Insights into Local Orbital Immunity: Evidence for the Involvement of the Th17 Cell Pathway in Thyroid-Associated Ophthalmopathy.

J Clin Endocrinol Metab 2018 Dec 3. Epub 2018 Dec 3.

Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai.

Context: Unique features of local immunity in thyroid-associated ophthalmopathy (TAO) may affect disease progression.

Objective: To investigate the association between the orbital immune microenvironment and TAO development.

Design/setting/participants: TAO and control orbital connective tissues were collected. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/advance-article/doi/10.1210/jc
Publisher Site
http://dx.doi.org/10.1210/jc.2018-01626DOI Listing
December 2018
9 Reads

Asymmetric lacrimal gland enlargement: an indicator for detection of pathological entities other than thyroid eye disease.

Graefes Arch Clin Exp Ophthalmol 2019 Feb 28;257(2):405-411. Epub 2018 Nov 28.

Department of Oculoplastic, Orbital, and Lacrimal Surgery, Aichi Medical University Hospital, 1-1 Yazako-Karimata, Nagakute, Aichi, 480-1195, Japan.

Purpose: To examine the clinicopathological characteristics of patients with thyroid eye disease (TED) who showed asymmetric lacrimal gland enlargement.

Methods: Sixteen patients were included in this retrospective, observational case series. The following data were collected: sex, age, laterality, past medical history, laboratory results for thyroid function and other autoimmune disorders, pathological results, other systemic lesions related to lacrimal gland pathology, and the clinical course after treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-018-4197-0DOI Listing
February 2019
3 Reads

Tocilizumab for thyroid eye disease.

Cochrane Database Syst Rev 2018 11 27;11:CD012984. Epub 2018 Nov 27.

Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London, UK, EC1V 2PD.

Background: Thyroid eye disease (TED) is an autoimmune disorder that constitutes a major clinical and therapeutic challenge. Current treatment options for moderate-to-severe TED include immunotherapy, orbital radiotherapy and decompression surgery. Limited drugs of proven efficacy are available for the treatment of people with TED. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD012984.pub2
Publisher Site
http://dx.doi.org/10.1002/14651858.CD012984.pub2DOI Listing
November 2018
24 Reads

Intraoperative relaxed muscle positioning technique results in a tertiary Center for Thyroid Orbitopathy Related Strabismus.

BMC Ophthalmol 2018 Nov 23;18(1):305. Epub 2018 Nov 23.

Department of Ophthalmology, Cerrahpasa Medical Faculty, Istanbul University, Cerrahpasa School of Medicine, 34098, Fatih, Istanbul, Turkey.

Background: Previous techniques resulted with low rates of successful fusion after the surgeries and high necessity of additional surgeries in the treatment of thyroid orbitopathy related strabismus. In this study, reviewing the results of our patients who had surgical correction with relaxed muscle positioning technique due to thyroid orbitopathy related strabismus to evaluate the effectiveness of the surgery was aimed.

Methods: The medical records of 8 patients who had surgical correction with intraoperative relaxed muscle positioning (IRMP) technique were studied retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12886-018-0974-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251154PMC
November 2018
3 Reads

Graves' disease in clinical perspective.

Front Biosci (Landmark Ed) 2019 01 1;24:35-47. Epub 2019 Jan 1.

Division for Specific Endocrinology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.

Graves' disease (GD) is the most common cause for hyperthyroidism in iodine-replete areas. The disease is caused by the appearance of stimulating TSH receptor autoantibodies (TRAb) leading to hyperthyroidism. Blocking and neutral TRAb have, however, also been described. Read More

View Article

Download full-text PDF

Source
January 2019
14 Reads

Oxidative stress markers in tears of patients with Graves' orbitopathy and their correlation with clinical activity score.

BMC Ophthalmol 2018 Nov 21;18(1):303. Epub 2018 Nov 21.

Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469, South Korea.

Background: To investigate the concentrations of oxidative stress markers, 8-hydroxy-2'-deoxyquanosine (8-OHdG) and malondialdehyde (MDA), in tears and their correlation with the clinical activity score (CAS) in patients with Graves' orbitopathy (GO) according to disease activity.

Methods: We recruited 27 participants with inactive stage GO, 35 participants with active stage GO, and 25 healthy controls without GO. The tear concentrations of 8-OHdG and MDA were determined by enzyme-linked immunosorbent assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12886-018-0969-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249971PMC
November 2018
5 Reads

Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.

Ocul Immunol Inflamm 2018 Nov 20:1-4. Epub 2018 Nov 20.

a Department of Internal Medicine , Dijon Bourgogne University Hospital , Dijon , France.

Purpose: To discuss the use of tocilizumab in mild to severe Graves' ophthalmopathy as corticosteroid-adjunctive therapy.

Methods: Retrospective case reports.

Results: Three patients with corticosteroid-resistant or advanced diplopia-associated Graves' ophthalmopathy were subsequently treated with monthly intravenous tocilizumab at a dose of 8 mg/kg. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2018.1545914DOI Listing
November 2018
7 Reads

Diagnosing and Treating Thyroid Ophthalmopathy.

Authors:
Rudolph S Wagner

J Pediatr Ophthalmol Strabismus 2018 Nov;55(6):355

View Article

Download full-text PDF

Source
https://www.healio.com/doiresolver?doi=10.3928/01913913-2018
Publisher Site
http://dx.doi.org/10.3928/01913913-20181008-01DOI Listing
November 2018
8 Reads

Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy.

Authors:
Terry J Smith

J Clin Endocrinol Metab 2019 Feb;104(2):581-594

Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, Ann Arbor, Michigan.

Context: Orbital tissues in thyroid-associated ophthalmopathy exhibit particular reactivity and undergo characteristic remodeling. Mechanisms underlying these changes have remained largely unexplained. Studies have characterized orbital connective tissues and derivative fibroblasts to gain insights into local manifestations of a systemic autoimmune syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-01493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320239PMC
February 2019
8 Reads

Flow Changes in Orbital Vessels Detected with Color Doppler Ultrasound in Patients with Early Dysthyroid Optic Neuropathy.

Acta Clin Croat 2018 Jun;57(2):301-306

Department of Ophthalmology, Rijeka University Hospital Center, Rijeka, Croatia.

Thyroid-associated orbitopathy (TAO) is a common manifestation of Graves' disease. The aim of the study was to assess the six percent of patients with TAO that develop dysthyroid optic neuropathy (DON), which is the most serious complication of TAO. As DON can cause perma-nent damage, it is essential to detect DON early when visual loss is still reversible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20471/acc.2018.57.02.10DOI Listing
June 2018
3 Reads

Antiglaucoma Medications Complicating the Management of Graves' Ophthalmopathy.

Ophthalmic Plast Reconstr Surg 2018 Nov/Dec;34(6):600-601

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000001230DOI Listing
November 2018
4 Reads